Evaluating the Challenges and Opportunities of Screening for Alpha Thalassemia Within the Beta Thalassemia Screening Program in the Islamic Republic of Iran

Document Type : Original Article(s)

Authors

1 MSc, Department of Epidemiology & Biostatistics, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran

2 Associate Professor, Department of Epidemiology & Biostatistics, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran

3 MD, Department of Genetics, Diseases Control Center, Ministry of Health and Medical Education, Tehran, Iran

4 Professor, Department of Epidemiology & Biostatistics, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Thalassemia screening instructions in Iran consider couples with MCV = 75-80, MCH = 26-27, HbA2<3.5, and HbF<3 indices as low-risk couples, and therefore further genetic testing is not obligatory. If the blood indices of alpha thalassemia carriers (One alpha gene deletion or two alpha gene deletions) fall within the parameters of low-risk couples, the identification of such couples within the beta thalassemia screening program will not be feasible. However, if the blood indicators of alpha thalassemia carriers fall within the range of the suspected high-risk couple, these couples can be identified through beta thalassemia screening instructions.
Methods: In this cross-sectional study, information was extracted from 2359 individuals diagnosed with alpha thalassemia, identified between 2018 and 2021, in 22 marriage counseling centers in Isfahan province using the results of the PND test. The blood indices MCV and MCH of alpha thalassemia carriers were compared with the low-risk and high-risk values of beta thalassemia carrier couples.
Findings: The average MCH and MCV of couples affected by alpha thalassemia gene deletions 1 and 2 are respectively within the low-risk and high-risk ranges for beta-thalassemia.
Conclusion: Beta thalassemia screening guidelines can effectively identify individuals with two alpha thalassemia gene deletions, although they have no effect in identifying those with one alpha gene deletion. Current guidelines indicate that it is possible to prevent the occurrence and complications of pregnancy in mothers with Bart's hemoglobin infants; however, the identification of H hemoglobin disease remains unfeasible.

Highlights

Mohammadreza Marasy:  Google Scholar

Keywords

Main Subjects

References

  1. Abuhelwa Z, Cheng J, Li J. Non-Neoplastic Hematologic Disorders: A Quick Review of Modern Diagnostic and Therapeutic Approaches. Berlin, Germany: Springer; 2024. p. 159-74.
  2. Coates TD, Roberts I. Introduction to a review series on globin disorders. Blood 2024; 144(8): 797-8.
  3. Dehbozorgian J, Moghadam M, Daryanoush S, Haghpanah S, Imani fard J, Aramesh A, et al. Distribution of alpha-thalassemia mutations in Iranian population. Hematology 2015; 20(6): 359-62.
  4. Harteveld CL, Higgs DR. α-thalassaemia. Orphanet J Rare Dis 2010; 5: 13.
  5. Singer ST. Variable clinical phenotypes of α-thalassemia syndromes. ScientificWorldJournal 2009; 9: 615-25.
  6. Songdej D, Fucharoen S. Alpha-thalassemia: diversity of clinical phenotypes and update on the treatment. Thalass. Rep 2022; 12(4): 157-72.
  7. Barka M, Mghirbi O, Taamli M, Brahem D, Soyed N, Khelifi A, et al. Hydrops fetalis: etiologies, management and outcome. Perinatal Journal 2024; 32(2024): 28-9.
  8. Sebastián de Lucas LM, Ordás Álvarez P, de Castro Marzo L, Illescas Molina T, Herrero B, Bartha JL, et al. Prenatal Management and Perinatal Outcome in a Large Series of Hydrops Fetalis. Fetal Diagn Ther 2024; 51(4): 335-42.
  9. Samavat A, Modell B. Iranian national thalassaemia screening programme. BMJ 2004; 329(7475): 1134-7.
  10. Hashemieh M, Naghadeh HT, Namini MT, Neamatzadeh H, Dehshal MH. The Iran thalassemia prevention program: success or failure? Iran J Ped Hematol Oncol 2015; 5(3): 161-6.
  11. Vichinsky E. Complexity of alpha thalassemia: growing health problem with new approaches to screening, diagnosis, and therapy. Ann N Y Acad Sci 2010; 1202(1): 180-7.
  12. Garshasbi M, Oberkanins C, Law HY, Neishabury M, Kariminejad R, Najmabadi H. alpha-globin gene deletion and point mutation analysis among in Iranian patients with microcytic hypochromic anemia. Haematologica 2003; 88(10): 1196-7.
  13. Jahangiri M, Rahim F, Malehi AS, Pezeshki SM, Ebrahimi M. Differential diagnosis of microcytic anemia, thalassemia or iron deficiency anemia: a diagnostic test accuracy meta-analysis. Mod Med Lab J 2020; 3(1): 16-29.
  14. Neishabury M, Abbasi L, Moheb, Poorfathollah AA, Kahrizi K, Keyhany E, et al. Alpha-Thalassemia: Deletion Analysis in Iran. Archives of Iranian Medicine 2001; 4(4): 160-4.
  15. Villegas A, Porres A, Sánchez J, González FA, Pérez-Clausell C, Martínez M, et al. Red blood cell phenotypes in alpha-thalassemias in the Spanish population. Haematologica 1998; 83(2): 99-103.
  16. Ahmad R, Saleem M, Aloysious NS, Yelumalai P, Mohamed N, Hassan S. Distribution of alpha thalassaemia gene variants in diverse ethnic populations in Malaysia: data from the Institute for Medical Research. Int J Mol Sci 2013; 14(9): 18599-614.
  17. Songdej D, Babbs C, Higgs DR. An international registry of survivors with Hb Bart's hydrops fetalis syndrome. Blood, The Journal of the American Society of Hematology 2017; 129(10): 1251-9.
  18. Chui DHK. α‐Thalassemia: Hb H disease and Hb Barts hydrops fetalis. Ann N Y Acad Sci 2005; 1054(1): 25-32.
  19. Li D, Liao C, Li J, Xie X, Huang Y, Zhong H. Detection of alpha-thalassemia in beta-thalassemia carriers and prevention of Hb Bart's hydrops fetalis through prenatal screening. Haematologica 2006; 91(5): 649-51.
  20. Vichinsky EP. Alpha thalassemia major—new mutations, intrauterine management, and outcomes. Hematology Am Soc Hematol Educ Program 2009; 2009(1): 35-41.
  21. Lal A, Vichinsky E. The clinical phenotypes of alpha thalassemia. Hematol Oncol Clin North Am 2023; 37(2): 327-39.
  22. Luo S, Chen X, Chen L, Zhong Q, Wang Q, Xu Z, et al. Analysis of Hb levels and degree of anemia in relation to genotype in 615 patients with hemoglobin H disease. Expert Rev Hematol 2020; 13(9): 1027-33.
  23. Chui DH, Fucharoen S, Chan V. Hemoglobin H disease: not necessarily a benign disorder. Blood 2003; 101(3): 791-800.
  24. Wahidin NK, Lai MI. Non-deletional alpha thalassaemia: a review of emerging therapy. Mal J Med Health Sci 2021; 17(Suppl 10): 72-84.
  25. Fucharoen S, Viprakasit V. Hb H disease: clinical course and disease modifiers. Hematology Am Soc Hematol Educ Program 2009; 2009: 26-34.
  26. Döğüş Y, Çürük P, Çürük A. Is genetic counseling important in hemoglobin H disease? Cukurova Medical Journal 2023; 48(2): 723-7.
  27. Godrati F, Saadatmand N, Dinpazhoh M, Akbarzadeh M. Epidemiological study of legal abortion due to fetal defects in the files referred to fars Province Forensic Medicine Centers from 2007 to 2013. Shiraz E-Medical Journal 2016; 17(11): e40023.
Journal of Isfahan Medical School
Volume 42, Issue 788
4th Week, December
November and December 2025
Pages 920-927

Files

History

  • Receive Date: 25 September 2024
  • Accept Date: 25 December 2024

Share

How to cite

Statistics